Pipeline

Advancing the CAR 2.0 Therapy Through the Clinical Trial Milestones

SynKIR™ has shown significant promise in in-vivo solid tumor and blood cancer models. The lead pipelines are currently under investigation in the First-in-Human Phase 1 Clinical Trials.  Early clinical data for SynKIR™-110 KIR-CAR show a positive safety profile, dose-dependent efficacy signals, and no dose-limiting toxicities. New pre-clinical data for SynKIR™-310 KIR-CAR show improved anti-tumor activity with reduced cytokine production compared to a conventional single-chain CAR T approach.